SLSSELLAS Life Sciences Group,...

Nasdaq sellaslifesciences.com


$ 1.46 $ 0.10 (7.3 %)    

Wednesday, 15-May-2024 15:55:25 EDT
QQQ $ 452.83 $ 6.97 (1.56 %)
DIA $ 399.31 $ 3.70 (0.94 %)
SPY $ 529.09 $ 6.48 (1.24 %)
TLT $ 92.14 $ 1.24 (1.36 %)
GLD $ 220.89 $ 2.80 (1.28 %)
$ 1.47
$ 1.38
$ 0.00 x 0
$ 0.00 x 0
$ 1.38 - $ 1.47
$ 0.50 - $ 1.91
1,452,340
na
65.88M
$ 1.29
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-14-2024 03-31-2024 10-Q
2 03-28-2024 12-31-2023 10-K
3 11-09-2023 09-30-2023 10-Q
4 08-10-2023 06-30-2023 10-Q
5 05-11-2023 03-31-2023 10-Q
6 03-16-2023 12-31-2022 10-K
7 11-14-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-31-2022 12-31-2021 10-K
11 11-12-2021 09-30-2021 10-Q
12 08-12-2021 06-30-2021 10-Q
13 05-13-2021 03-31-2021 10-Q
14 03-23-2021 12-31-2020 10-K
15 11-13-2020 09-30-2020 10-Q
16 08-13-2020 06-30-2020 10-Q
17 05-14-2020 03-31-2020 10-Q
18 03-13-2020 12-31-2019 10-K
19 11-14-2019 09-30-2019 10-Q
20 08-14-2019 06-30-2019 10-Q
21 05-15-2019 03-31-2019 10-Q
22 03-22-2019 12-31-2018 10-K
23 11-14-2018 09-30-2018 10-Q
24 08-14-2018 06-30-2018 10-Q
25 05-15-2018 03-31-2018 10-Q
26 04-13-2018 12-31-2017 10-K
27 11-09-2017 09-30-2017 10-Q
28 08-14-2017 06-30-2017 10-Q
29 05-10-2017 03-31-2017 10-Q
30 03-15-2017 12-31-2016 10-K
31 11-09-2016 09-30-2016 10-Q
32 08-09-2016 06-30-2016 10-Q
33 05-10-2016 03-31-2016 10-Q
34 03-10-2016 12-31-2015 10-K
35 11-09-2015 09-30-2015 10-Q
36 08-06-2015 06-30-2015 10-Q
37 05-07-2015 03-31-2015 10-Q
38 03-05-2015 12-31-2014 10-K
39 11-05-2014 09-30-2014 10-Q
40 08-11-2014 06-30-2014 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 sellas-life-sciences-gr-q1-2024-adj-eps-021-misses-016-estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.21) per share which missed the analyst consensus estimate...

 sellas-life-sciences-announces-recommendation-of-independent-data-monitoring-committee-following-completion-of-enrollment-in-regal-phase-3-study

– Based on the Efficacy and Safety Data Assessed, the Independent Data Monitoring Committee (IDMC) Recommends Continuation of P...

 sellas-life-sciences-gr-q4-eps-025-misses-021-estimate

SELLAS Life Sciences Gr (NASDAQ:SLS) reported quarterly losses of $(0.25) per share which missed the analyst consensus estimate...

 sellas-announces-topline-data-from-phase-2a-study-of-sls009-in-relapsedrefractory-acute-myeloid-leukemia-and-provides-steering-committee-update-on-phase-3-regal-study

Phase 3 REGAL Study of GPS in AML: Enrollment Completed; Steering Committee Guided Interim Analysis Imminent; IDMC Now Schedu...

 dow-falls-over-200-points-adobe-shares-plunge

U.S. stocks traded lower toward the end of trading, with the Dow Jones index falling over 200 points on Friday. The Dow traded...

 why-jabil-shares-are-trading-lower-by-over-14-here-are-other-stocks-moving-in-fridays-mid-day-session

Shares of Jabil Inc. (NYSE: JBL) fell sharply during Friday’s session after the company reported financial second-quarter resu...

 crude-oil-edges-lower-us-consumer-sentiment-falls-in-march

U.S. stocks traded lower midway through trading, with the Dow Jones index falling over 100 points on Friday. The Dow traded do...

 nasdaq-down-over-100-points-hibbett-reports-downbeat-sales

U.S. stocks traded lower this morning, with the Nasdaq Composite falling more than 100 points on Friday. Following the market ...

 sellas-life-sciences-delivers-oral-presentation-of-sls009-phase-1-data-for-acute-myeloid-leukemia-patients-at-2024-european-school-of-haematology-conference

- All key study objectives regarding pharmacokinetic, pharmacodynamic, safety, and clinical activity were met -- Complete remis...

 sellas-announces-publication-of-preclinical-data-on-its-highly-selective-cdk9-inhibitor-sls009-in-oncotarget

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS'' or the "Company"), a late-stage clinical biopharma...

 sellas-life-sciences-to-present-sls009-phase-1-data-from-acute-myeloid-leukemia-patients-at-the-2024-european-school-of-haematology-conference

SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) ("SELLAS" or the "Company"), a late-stage clinical biopharmaceuti...

 zijin-mining-invests-97m-in-solaris-resources-deal-to-bolster-copper-project-in-ecuador

China-based Zijin Mining is investing $97 million in Solaris Resources. Proceeds will go toward an Ecuador-based project.

 sellas-life-sciences-receives-fda-fast-track-designation-for-sls009-for-treatment-of-relapsedrefractory-acute-myeloid-leukemia-and-provides-updated-data-for-phase-2a-study-of-sls009-in-relapsedrefractory-acute-myeloid-leukemia-patients

- Phase 2a Enrollment Completed in 45 mg Safety Cohort: Median Overall Survival (OS) Not Reached; 89% of Patients Alive with Si...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION